Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling.
about
Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis.Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy.Solitary splenic metastasis from nasopharyngeal carcinoma: a case report and systematic review of the literatureOmics-based identification of biomarkers for nasopharyngeal carcinomaSAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinomaOpportunities and limitations of SELDI-TOF-MS in biomedical research: practical advicesSerum amyloid A: an acute-phase protein involved in tumour pathogenesisMass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations.Proteomic approach to biomarker discovery in cancer tissue from lung adenocarcinoma among nonsmoking Chinese women in Hong Kong.Proteomic analysis of blood level of proteins before and after operation in patients with esophageal squamous cell carcinoma at high-incidence area in Henan Province.Protein profiling in respiratory disease: techniques and impact.Preliminary study on proteomics of gastric carcinoma and its clinical significance.Human body fluid proteome analysis.Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.Inflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins.Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosisSerum amyloid A: a novel biomarker for endometrial cancer.A combined biomarker pattern improves the discrimination of lung cancer.MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer.Association between plasma proteome profiles analysed by mass spectrometry, a lymphocyte-based DNA-break repair assay and radiotherapy-induced acute mucosal reaction in head and neck cancer patients.Improving Detection Accuracy of Lung Cancer Serum Proteomic Profiling via Two-Stage Training Process.Identification of potential serum biomarkers for Wilms tumor after excluding confounding effects of common systemic inflammatory factors.Identifying FGA peptides as nasopharyngeal carcinoma-associated biomarkers by magnetic beads.Periostin, a stroma-associated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma.Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinomaMass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Nasopharyngeal carcinoma: molecular biomarker discovery and progress.Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers.MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment.Population proteomics: addressing protein diversity in humans.Dual effect of serum amyloid A on the invasiveness of glioma cells.Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma.Quantitation of target proteins and post-translational modifications in affinity-based proteomics approaches.Expression of serum amyloid A transcripts in human bone tissues, differentiated osteoblast-like stem cells and human osteosarcoma cell lines.Mass spectrometry-based proteomic profiling of lung cancer.Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.Serum biomarkers for early detection of gynecologic cancers.Ultrasensitive Luminescent In Vitro Detection for Tumor Markers Based on Inorganic Lanthanide Nano-Bioprobes.Update on biomarkers for the detection of lung cancer.
P2860
Q24810591-B0B59A12-EEBB-4B5C-B586-8A9CF2B64031Q24817009-B0891CF7-E58A-4CF9-A002-2DC392F3F241Q26740041-C32A1DBC-554B-40C7-BBA7-C4DE84936E7EQ28082480-0C2C5F82-C78B-4C51-A7C9-CBFA22C44C78Q28235586-8F4C2C08-8FCD-49B0-A160-20E96CD2C09CQ28287384-2BD37283-2F73-457C-8EE8-07A1D0D22912Q28291806-DA08D23A-7F03-446D-A5FE-8F4C24F8FB0DQ30751781-0B8F0BC8-DA41-4A96-8C73-4B62813492ACQ30840907-1513D700-45FB-4F59-A554-402E8248AD65Q33207901-4B6DE196-BAD7-45F8-A7EB-74410BD088B4Q33217465-9FF2EA56-6242-41AF-8ACA-D35AFEB4F74EQ33231849-379BA0BA-314A-43E9-966B-2919FD3A6070Q33262623-363408D4-1E6C-4688-AD50-0C8D7A752228Q33301109-2DFA5AE9-0125-4C1F-A837-60418780FE80Q33517207-384803DA-C759-4610-9FCF-90F8206C735CQ33587249-E4CB7A22-29F5-45D8-B19C-C2491BC3F913Q33643221-7965435C-3339-40E6-BD6A-33967156195FQ33724593-6898BD7D-7389-42E1-A427-81790900DC35Q33793178-AF77F159-C6C0-4843-BF5E-41CDBE1175E9Q33829971-E4B5874E-3E31-448D-8C38-CC12FD70693DQ33874499-B8AF866D-A91A-4AB2-85E6-980B34E6D23CQ34097044-81944B02-04D9-4F76-BD6B-ABE71BBDDEF8Q34159066-34CCF6EC-09EF-4DDB-8335-C490AF0A2AE6Q34307249-537C4DC2-65F8-4CAD-8A40-C79830B98C29Q34392042-B23832AC-09C3-4DE1-BFC5-C1F8ABA22307Q35238008-3A46209C-A871-4E82-8ED1-48C03BCE6BABQ35597559-DE12A50F-CBD5-4C4F-B3F9-526296B6A3ECQ36088189-B4F236B2-9D56-4DBF-903B-35D3515E8C69Q36147848-D88C7669-7E8C-4982-85BB-065C287D2459Q36184782-6CFA9917-6B82-49F4-8EDB-B5FF32432532Q36682802-5BC2ED1E-A7BC-4FA0-8370-8EB8C8821F29Q36700050-AD9D75B0-4FCE-44F0-A2D2-58FB87E6097FQ36841893-EA329381-37EA-4E15-AD30-F9B1907D7E36Q36884024-D0FDC45D-5BF2-4887-BEAA-F7F96AD91AFBQ37171914-CAD01D1F-9852-452A-B2D7-59712635BE7AQ37183598-56B64EA4-ED32-4C78-AAEF-ACB892941BF7Q37287461-86211AC9-F876-421B-9C18-7787DF94C97EQ37328423-3B8EA969-593A-461A-83D6-BD6EF09ADAF9Q37404644-EB956479-23C9-47F3-B9DC-8798ADAE9D77Q37645219-EF12FA81-9E31-41B0-B4A6-DC34307CA970
P2860
Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Identification of serum amyloi ...... by serum proteomic profiling.
@en
Identification of serum amyloi ...... by serum proteomic profiling.
@nl
type
label
Identification of serum amyloi ...... by serum proteomic profiling.
@en
Identification of serum amyloi ...... by serum proteomic profiling.
@nl
prefLabel
Identification of serum amyloi ...... by serum proteomic profiling.
@en
Identification of serum amyloi ...... by serum proteomic profiling.
@nl
P2093
P1476
Identification of serum amyloi ...... by serum proteomic profiling.
@en
P2093
Cadmon K P Lim
Christine Yip
Joseph S K Au
Roger K C Ngan
Stephen C K Law
Tai-Tung Yip
Timothy T C Yip
Vanitha Thulasiraman
Victor W S Ma
Victor Yip
P356
10.1158/1078-0432.CCR-0413-3
P407
P433
P577
2004-01-01T00:00:00Z